BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers 2015;104:291-309. [PMID: 25663018 DOI: 10.1002/bip.22623] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Musharrafieh R, Ma C, Zhang J, Smee DF, DeGrado WF, Wang J. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. Antiviral Res 2017;140:45-54. [PMID: 28087313 DOI: 10.1016/j.antiviral.2017.01.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
2 Ren Y, Chen Y, Cao S. Targeted inhibition of the endonuclease activity of influenza polymerase acidic proteins. Future Med Chem 2022. [PMID: 35213253 DOI: 10.4155/fmc-2021-0264] [Reference Citation Analysis]
3 Arns S, Balgi AD, Shimizu Y, Pfeifer TA, Kumar N, Shidmoossavee FS, Sun S, Tai SS, Agafitei O, Jaquith JB, Bourque E, Niikura M, Roberge M. Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel. Eur J Med Chem 2016;120:64-73. [PMID: 27187859 DOI: 10.1016/j.ejmech.2016.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Jalily PH, Duncan MC, Fedida D, Wang J, Tietjen I. Put a cork in it: Plugging the M2 viral ion channel to sink influenza. Antiviral Res 2020;178:104780. [PMID: 32229237 DOI: 10.1016/j.antiviral.2020.104780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
5 Musharrafieh R, Ma C, Wang J. Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. Eur J Pharm Sci 2020;141:105124. [PMID: 31669761 DOI: 10.1016/j.ejps.2019.105124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
6 Kuznetsov NY, Tikhov RM, Godovikov IA, Medvedev MG, Lyssenko KA, Burtseva EI, Kirillova ES, Bubnov YN. Stereoselective synthesis of novel adamantane derivatives with high potency against rimantadine-resistant influenza A virus strains. Org Biomol Chem 2017;15:3152-7. [PMID: 28338150 DOI: 10.1039/c7ob00331e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
7 Naesens L, Stevaert A, Vanderlinden E. Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol 2016;30:106-15. [PMID: 27570127 DOI: 10.1016/j.coph.2016.08.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
8 Wang Y, Hu Y, Xu S, Zhang Y, Musharrafieh R, Hau RK, Ma C, Wang J. In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. J Med Chem 2018;61:1074-85. [PMID: 29341607 DOI: 10.1021/acs.jmedchem.7b01536] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
9 Zhang J, Hu Y, Hau R, Musharrafieh R, Ma C, Zhou X, Chen Y, Wang J. Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses. Eur J Pharm Sci 2019;133:86-94. [PMID: 30930289 DOI: 10.1016/j.ejps.2019.03.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
10 Musharrafieh R, Ma C, Wang J. Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res 2018;153:10-22. [PMID: 29518414 DOI: 10.1016/j.antiviral.2018.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Dudev T, Grauffel C, Lim C. Influence of the Selectivity Filter Properties on Proton Selectivity in the Influenza A M2 Channel. J Am Chem Soc 2016;138:13038-47. [DOI: 10.1021/jacs.6b08041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Leiva R, Barniol-Xicota M, Codony S, Ginex T, Vanderlinden E, Montes M, Caffrey M, Luque FJ, Naesens L, Vázquez S. Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion. J Med Chem 2018;61:98-118. [PMID: 29220568 DOI: 10.1021/acs.jmedchem.7b00908] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
13 Musharrafieh R, Lagarias P, Ma C, Hau R, Romano A, Lambrinidis G, Kolocouris A, Wang J. Investigation of the Drug Resistance Mechanism of M2-S31N Channel Blockers through Biomolecular Simulations and Viral Passage Experiments. ACS Pharmacol Transl Sci 2020;3:666-75. [PMID: 32832869 DOI: 10.1021/acsptsci.0c00018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35. [PMID: 30218908 DOI: 10.1016/j.ejmech.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wang J. M2 as a target to combat influenza drug resistance: what does the evidence say? Future Virology 2016;11:1-4. [DOI: 10.2217/fvl.15.95] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhang Y, Zhang H, Zheng Q. A unique activation-promotion mechanism of the influenza B M2 proton channel uncovered by multiscale simulations. Phys Chem Chem Phys 2019;21:2984-91. [PMID: 30672572 DOI: 10.1039/c9cp00130a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhang Y, Zheng QC. In Silico Analysis Revealed a Unique Binding but Ineffective Mode of Amantadine to Influenza Virus B M2 Channel. J Phys Chem Lett 2021;12:1169-74. [PMID: 33480694 DOI: 10.1021/acs.jpclett.0c03560] [Reference Citation Analysis]
18 Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection. J Med Virol 2021;93:4638-46. [PMID: 33792930 DOI: 10.1002/jmv.26990] [Reference Citation Analysis]
19 Li F, Ma C, DeGrado WF, Wang J. Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. J Med Chem 2016;59:1207-16. [PMID: 26771709 DOI: 10.1021/acs.jmedchem.5b01910] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
20 Yang J, Du J, Huang C, Wang T, Huang L, Yang S, Li L. Discovery of 5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazin-2(1H)-one derivatives as new potent PB2 inhibitors. Bioorganic & Medicinal Chemistry Letters 2019;29:1609-13. [DOI: 10.1016/j.bmcl.2019.04.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Zhang J, Hu Y, Wu N, Wang J. Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay. ACS Chem Biol 2020;15:74-82. [PMID: 31714745 DOI: 10.1021/acschembio.9b00552] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
22 Llabrés S, Juárez-jiménez J, Masetti M, Leiva R, Vázquez S, Gazzarrini S, Moroni A, Cavalli A, Luque FJ. Mechanism of the Pseudoirreversible Binding of Amantadine to the M2 Proton Channel. J Am Chem Soc 2016;138:15345-58. [DOI: 10.1021/jacs.6b07096] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
23 Wu S, Huang J, Gazzarrini S, He S, Chen L, Li J, Xing L, Li C, Chen L, Neochoritis CG, Liao GP, Zhou H, Dömling A, Moroni A, Wang W. Isocyanides as Influenza A Virus Subtype H5N1 Wild-Type M2 Channel Inhibitors. ChemMedChem 2015;10:1837-45. [DOI: 10.1002/cmdc.201500318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
24 Thomaston JL, Polizzi NF, Konstantinidi A, Wang J, Kolocouris A, DeGrado WF. Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters. J Am Chem Soc 2018;140:15219-26. [PMID: 30165017 DOI: 10.1021/jacs.8b06741] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
25 Li F, Hu Y, Wang Y, Ma C, Wang J. Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction. J Med Chem 2017;60:1580-90. [PMID: 28182419 DOI: 10.1021/acs.jmedchem.6b01852] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
26 Hu Y, Zhang J, Musharrafieh RG, Ma C, Hau R, Wang J. Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antiviral Res 2017;145:103-13. [PMID: 28778830 DOI: 10.1016/j.antiviral.2017.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
27 Zhang J, Hu Y, Musharrafieh R, Yin H, Wang J. Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development. Curr Med Chem 2019;26:2243-63. [PMID: 29984646 DOI: 10.2174/0929867325666180706112940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
28 Santner P, Martins JMDS, Laursen JS, Behrendt L, Riber L, Olsen CA, Arkin IT, Winther JR, Willemoës M, Lindorff-Larsen K. A Robust Proton Flux (pHlux) Assay for Studying the Function and Inhibition of the Influenza A M2 Proton Channel. Biochemistry 2018;57:5949-56. [PMID: 30230312 DOI: 10.1021/acs.biochem.8b00721] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
29 Zhang J, Hu Y, Foley C, Wang Y, Musharrafieh R, Xu S, Zhang Y, Ma C, Hulme C, Wang J. Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance. Sci Rep 2018;8:4653. [PMID: 29545578 DOI: 10.1038/s41598-018-22875-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
30 Cáceres CJ, Hu Y, Cárdenas-García S, Wu X, Tan H, Carnaccini S, Gay LC, Geiger G, Ma C, Zhang QY, Rajao D, Perez DR, Wang J. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. Emerg Microbes Infect 2021;10:1832-48. [PMID: 34427541 DOI: 10.1080/22221751.2021.1972769] [Reference Citation Analysis]
31 Khomenko TM, Zarubaev VV, Orshanskaya IR, Kadyrova RA, Sannikova VA, Korchagina DV, Volcho KP, Salakhutdinov NF. Anti-influenza activity of monoterpene-containing substituted coumarins. Bioorg Med Chem Lett 2017;27:2920-5. [PMID: 28501512 DOI: 10.1016/j.bmcl.2017.04.091] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
32 Li F, Ma C, Hu Y, Wang Y, Wang J. Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel. ACS Infect Dis 2016;2:726-33. [PMID: 27657178 DOI: 10.1021/acsinfecdis.6b00130] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
33 Barniol-Xicota M, Gazzarrini S, Torres E, Hu Y, Wang J, Naesens L, Moroni A, Vázquez S. Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus. J Med Chem 2017;60:3727-38. [PMID: 28418242 DOI: 10.1021/acs.jmedchem.6b01758] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Aledavood E, Selmi B, Estarellas C, Masetti M, Luque FJ. From Acid Activation Mechanisms of Proton Conduction to Design of Inhibitors of the M2 Proton Channel of Influenza A Virus. Front Mol Biosci 2022;8:796229. [DOI: 10.3389/fmolb.2021.796229] [Reference Citation Analysis]
35 McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 2016;129:21-38. [PMID: 26872862 DOI: 10.1016/j.antiviral.2016.01.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
36 Cui H, Zhang C, Zhao Z, Zhang C, Fu Y, Li J, Chen G, Lai M, Li Z, Dong S, Chen L, Li Z, Wang C, Liu J, Gao Y, Guo Z. Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity. Virol J 2020;17:12. [PMID: 32000791 DOI: 10.1186/s12985-020-1283-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Hou L, Zhang Y, Ju H, Cherukupalli S, Jia R, Zhang J, Huang B, Loregian A, Liu X, Zhan P. Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins. Acta Pharmaceutica Sinica B 2022;12:1805-24. [DOI: 10.1016/j.apsb.2021.11.018] [Reference Citation Analysis]
38 Mandour YM, Breitinger U, Ma C, Wang J, Boeckler FM, Breitinger HG, Zlotos DP. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7. Drug Des Devel Ther 2018;12:1019-31. [PMID: 29750015 DOI: 10.2147/DDDT.S157104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
39 Hu Y, Wang Y, Li F, Ma C, Wang J. Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. Eur J Med Chem 2017;135:70-6. [PMID: 28433777 DOI: 10.1016/j.ejmech.2017.04.038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
40 Lin X, Qin-Hua C, Peng L, Chun-Lei L, Guang-De Y. The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors. Chem Biol Drug Des 2018;91:105-15. [PMID: 28646621 DOI: 10.1111/cbdd.13060] [Reference Citation Analysis]
41 Gordon NA, McGuire KL, Wallentine SK, Mohl GA, Lynch JD, Harrison RG, Busath DD. Divalent copper complexes as influenza A M2 inhibitors. Antiviral Res 2017;147:100-6. [PMID: 29032206 DOI: 10.1016/j.antiviral.2017.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
42 Hu Y, Sneyd H, Dekant R, Wang J. Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target. Curr Top Med Chem 2017;17:2271-85. [PMID: 28240183 DOI: 10.2174/1568026617666170224122508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
43 Dong J, Xiao M, Ma Q, Zhang G, Zhao W, Kong M, Zhang Y, Qiu L, Hu W. Design and synthesis of pinane oxime derivatives as novel anti-influenza agents. Bioorg Chem 2020;102:104106. [PMID: 32739481 DOI: 10.1016/j.bioorg.2020.104106] [Reference Citation Analysis]
44 Liu H, Jiang C, Wu Y, Wu M, Wu J, Zhao G, Sun J, Huang X, Li J, Sheng R, Barbier J, Cintrat J, Gillet D, Su W. Antiviral Effects of ABMA and DABMA against Influenza Virus In Vitro and In Vivo via Regulating the Endolysosomal Pathway and Autophagy. IJMS 2022;23:3940. [DOI: 10.3390/ijms23073940] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ma C, Li F, Musharrafieh RG, Wang J. Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance. Antiviral Res. 2016;133:62-72. [PMID: 27478032 DOI: 10.1016/j.antiviral.2016.07.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
46 Hu Y, Zhang J, Musharrafieh R, Hau R, Ma C, Wang J. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. Int J Mol Sci 2017;18:E1929. [PMID: 28885544 DOI: 10.3390/ijms18091929] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
47 Musharrafieh R, Lagarias PI, Ma C, Tan GS, Kolocouris A, Wang J. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers. Mol Pharmacol 2019;96:148-57. [PMID: 31175183 DOI: 10.1124/mol.119.116640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
48 Santner P, Martins JMDS, Kampmeyer C, Hartmann-Petersen R, Laursen JS, Stein A, Olsen CA, Arkin IT, Winther JR, Willemoës M, Lindorff-Larsen K. Random Mutagenesis Analysis of the Influenza A M2 Proton Channel Reveals Novel Resistance Mutants. Biochemistry 2018;57:5957-68. [PMID: 30230310 DOI: 10.1021/acs.biochem.8b00722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ma C, Zhang J, Wang J. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers. Mol Pharmacol 2016;90:188-98. [PMID: 27385729 DOI: 10.1124/mol.116.105346] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]